Clinical trials: Chimeric Antigen Receptor T-cell Therapy
Lymphoma, Myeloma
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
This study is for patients who have a type of cancer that expresses the protein CD70, which includes lymphoma (lymph gland cancer), myeloma and solid tumors including some sarcomas and kidney cancers, and the cancer has come back…
- Conditions
- Lymphoma, Myeloma, Solid Tumors, Sarcoma
- Trial name
- CALySSEY (NCT07297160)
- Testing
- Dose Level -1, Dose Level 1 (starting dose level), Dose Level 2
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
Glioblastoma Multiforme
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
The purpose of this study is to test the safety of using T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (CAR.B7-H3T cells) in patients with glioblastoma.
- Trial name
- NCT05366179
- Testing
- CAR.B7-H3T cells infusion
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Adverse Drug Reactions, Cancer
Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events
CAR-T cells and cellular therapies may lead to various adverse reactions. This study investigates reports of different toxicities for cellular therapies in the World Health Organization's (WHO) global database of individual…
- Trial name
- CARTABLE (NCT04279470)
- Testing
- CAR T-cell and Cellular Therapies
- Where
- France
- Volunteers
- 100,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
EBV Associated Lymphoid Neoplasms
GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms
This is a Phase 1/Phase 2 open-label, single-arm clinical study of GP350 CAR-T for Relapse/Refractory and Epstein-Barr virus infection associated lymphoid neoplasms.
- Trial name
- ANXIN-02 (NCT07306156)
- Testing
- GP350 CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhimin Zhai
Multiple Myeloma
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
This study will test the safety of the study treatment, MCARH109, at different doses, to see which dose is safest in people, and to look for any good and bad effects of this treatment.
- Trial name
- NCT04555551
- Testing
- Infusion of MCARH109 T cells
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
B-ALL
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia
- Trial name
- NCT04499573
- Testing
- CD19/CD22 CAR-T
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
CDH17-positive Advanced Malignant Solid Tumors
Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-CDH17 CAR-T cell injection in patients with CDH17-positive advanced malignant solid tumors.
- Trial name
- NCT06501183
- Testing
- Anti-CDH17 CAR-T cells
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Shanghai Pudong Hospital
Multiple Myeloma
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).
- Trial name
- CARTITUDE-4 (NCT04181827)
- Testing
- Cilta-cel, Pomalidomide, Bortezomib
- Where
- 88 sites in United States, Australia and 14 more
- Volunteers
- 419 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed and/or Refractory Acute Lymphoblastic Leukemia, Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma
CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
A study of CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
- Trial name
- NCT04609241
- Testing
- CD79b CAR-T Cells
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Zhejiang University
Solid Tumor
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of UCLM802 (Anti-Mesothelin CAR-T) cell injection in patients with Mesothelin-positive advanced malignant…
- Trial name
- NCT05775666
- Testing
- UCLM802 Cell Injection
- Volunteers
- 87 people
- Sponsor
- Peking University
Hematologic Cancer
Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy
The goal of this clinical trial is to learn if two non-pharmacological strategies can help reduce neurotoxicity caused by CAR-T cell therapy in adult patients with hematologic cancer, both sexes, aged 18 to 80 years.
- Trial name
- CARE-T (NCT07173166)
- Testing
- Physical activity, Physical activity and nutrition
- Where
- 2 sites in Spain
- Volunteers
- 338 people
- Sponsor
- Instituto de Investigacion Sanitaria INCLIVA
Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory…
- Trial name
- NCT07115745
- Testing
- BMS-986515, Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 125 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
B-cell Acute Lymphoblastic Leukemia
Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
A Clinical Study on the Safety and Effectiveness of donor derived CD19 CAR-T Cells in the treatment of R/R B-cell acute lymphoblastic leukemia
- Trial name
- NCT06793241
- Testing
- CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhejiang University
Lymphoma
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
Patients with relapsed or refractory lymphoma often develop resistance to chemotherapy. Chimeric antigen receptor-modified T cell (CART) therapy showed promising effect in B-cell malignancies these years.
- Trial name
- NCT03468153
- Testing
- Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Prolonged Cytopenia Following CAR-T Therapy
Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy
This is a prospective, single-arm, single-center clinical study designed to evaluate the safety of autologous hematopoietic stem cell infusion for the treatment of prolonged cytopenia following CAR-T cell therapy.
- Trial name
- ICAHT-001 (NCT07127289)
- Testing
- Autologous hematopoietic stem cell infusion
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
CRC (Colorectal Cancer), Metastatic Colorectal Cancer
Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer
This is an investigator initiated trial to assess the efficacy and safety of a GCC-targeting CAR-T therapy (REVO-UWD-01) in the metastatic colorectal cancer.
- Trial name
- Wondercel-UWD1 (NCT06653010)
- Testing
- Universal CAR-T cells injection for treating mCRC
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Wondercel Biotech (ShenZhen)
Plasma Cell Myeloma
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
This phase II trial studies the effect of pembrolizumab in treating patients with multiple myeloma that is growing, spreading, or getting worse (progressing) on chimeric antigen receptor (CAR)-T cell therapy.
- Trial name
- NCT05204160
- Testing
- Pembrolizumab
- Where
- United States
- Sponsor
- Emory University
Multiple Myeloma Refractory, Multiple Myeloma Progression
Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)
This is a prospective, single-arm, open-label, early exploratory clinical study designed to evaluate the safety, tolerability, and efficacy of the DQ1001 cell product in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT07622862
- Testing
- Allogeneic, off-the-shelf CAR-T cell injection targeting BCMA and GPRC5D
- Volunteers
- 16 people
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
Multiple Myeloma
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
This is a multicenter, open-label, dose-escalation/expansion phase 1/2a study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and determine the recommended dose of KQ-2003 CAR T-cells for…
- Trial name
- NCT06223646
- Testing
- KQ-2003 CAR T-cells
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
B-cell Acute Lymphoblastic Leukemia, B-ALL
Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
This is a single-arm, single-center, open-labeled clinical study to evaluate the safety and efficacy of UCAR-T Cells injection for patients with relapsed/refractory(r/r) B-cell Acute Lymphoblastic Leukemia(B-ALL).
- Trial name
- NCT05639179
- Testing
- UCAR-T Cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.